statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Analyst Ratings For Allogene Therapeutics

Latest Ratings for ALLO
 DateFirmActionFromTo Mar 2022Goldman SachsMaintainsNeutral Dec 2021RBC CapitalMaintainsOutperform Oct 2021JMP SecuritiesMaintainsMarket Outperform
 View More Analyst...

Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views

DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Allogene Therapeutics (ALLO, $4.38) price exceeded its 50-day Moving Average on April 01, 2024

This price move could indicate a change in the trend, and may be a sell signal for investors...

Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside

Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside...

Analysts Set Expectations for Allogene Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Research analysts at Zacks Research issued their FY2026 earnings per share (EPS) estimates for Allogene Therapeutics in a research report...

Allogene Therapeutics (ALLO, $4.46) Stochastic Oscillator left the oversold zone on March 28, 2024

This is a signal that ALLO's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Allogene Therapeutics (ALLO, $4.26) price exceeded its 50-day Moving Average on March 22, 2024

Allogene Therapeutics (NASDAQ:ALLO) Receives "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO  Free Report) in a research note released on Tuesday morning, Benzinga reports. HC Wainwright...

Allogene Therapeutics (NASDAQ:ALLO) Stock Rating Reaffirmed by HC Wainwright

Allogene Therapeutics (NASDAQ:ALLO  Get Free Report)s stock had its buy rating reissued by stock analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports...

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Volume	1.6M
52-Wk High	$5.78
52-Wk Low	$2.01

ALLO Allogene Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community